Ken Griffin Tandem Diabetes Care Inc Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$30.43 - $53.43 $386,461 - $678,561	12,700 Added 14.37%	101,100 $4.07 Million
Q1 2024 May 15, 2024	BUY	$22.09 - $35.41 $777,568 - $1.25 Million	35,200 Added 66.17%	88,400 $3.13 Million
Q4 2023 Feb 14, 2024	BUY	$14.28 - $31.03 $57,120 - $124,120	4,000 Added 8.13%	53,200 $1.57 Million
Q3 2023 Nov 14, 2023	BUY	$19.33 - $36.22 $328,610 - $615,740	17,000 Added 52.8%	49,200 $1.02 Million
Q2 2023 Aug 14, 2023	SELL	$24.18 - $42.46 $408,642 - $717,574	-16,900 Reduced 34.42%	32,200 $790,000
Q1 2023 May 15, 2023	SELL	$35.86 - $46.5 $3.78 Million - $4.9 Million	-105,300 Reduced 68.2%	49,100 $1.99 Million
Q4 2022 Feb 14, 2023	BUY	$35.49 - $56.15 $1.32 Million - $2.09 Million	37,200 Added 31.74%	154,400 $6.94 Million
Q3 2022 Nov 14, 2022	SELL	$43.76 - $68.97 $761,424 - $1.2 Million	-17,400 Reduced 12.93%	117,200 $5.61 Million

344

72.7M

3.12M

343K

Ticker TNDM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 64,221,200
Market Cap $2.64B
Description
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin c...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.